Additional Supporting Information may be found in the online version of this article.

HEP_25875_sm_SuppFig1.tiff2641KSupporting Information Figure 1. TCR-L binding ability in HBV producing HepG2 cell lines. Control HepG2 cells and HepG2 -13 (HBV producing cells) were fixed in 1%PFA, and stained with cTCR-L or sTCR-L. Alexa Fluor-647-Tyramide Signal Amplification kit was used to visualize the antibody binding (red). Nuclei were stained with DAPI (blue).
HEP_25875_sm_SuppFig2.tif1593KSupporting Information Figure 2. HepG2 cells were transfected with pISRE-Luc reporter vector, pulsed with or without 10μg/ml HBs183-91 peptide and treated with 3-fold serially diluted IFNα, sTCR-L, or sTCR-L/IFNα. Luciferase activity was measured 48h post-treatment.
HEP_25875_sm_SuppFig3.tiff1572KSupporting Information Figure 3. TCR-L/IFNα trigger CXCL-10 production on IFNγ treated Hepg2 cells. CXCL-10 production was measured by intracellular CXCL-10 in HepG2 cells. HepG-2 cells were incubated with IFNγ, not pulsed or pulsed with HBs183-91 peptide (1μM) and incubated with the indicated TCR-L overnight. Bars represented the % of CXCL-10 positive cells obtained with the different conditions. Inserted hystogram displayed mean fluorescence intensity (MFI) of the Hbs183-91 peptide pulsed target cells treated with sTCR-L/IFNα, sTCR-L or cTCR-L/IFNα.
HEP_25875_sm_SuppInfo.doc59KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.